Ardelyx, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. The filing was signed March 5, 2015. Ardelyx is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue; results were primarily driven by collaboration payments and development reimbursements.
Business context and pipeline
- Lead candidate tenapanor is partnered worldwide with AstraZeneca, which funds its development and commercialization. Ardelyx retained U.S. co-promotion rights and an option to co-fund the first Phase 3 program.
- Tenapanor’s Phase 2b IBS-C trial met its primary endpoint at 50 mg twice daily. The Phase 2b CKD-5D hyperphosphatemia trial also met its primary endpoint, with a dose-related reduction in serum phosphate.
- In February 2014, Ardelyx licensed its NaP2b inhibitor research program to Sanofi; Sanofi may exercise an option for an exclusive development and commercialization license. Other internal programs remained at the research stage.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $31.6 million | $28.9 million |
| Licensing revenue | $18.4 million | $8.1 million |
| Collaborative development revenue | $13.2 million | $20.9 million |
| Research and development expense | $25.9 million | $28.1 million |
| General and administrative expense | $7.3 million | $3.7 million |
| Operating loss | $1.6 million | $2.9 million |
| Net loss | $3.2 million | $6.6 million |
| Cash from operating activities | $13.4 million | $1.8 million |
- Revenue increased 9% year over year. Licensing revenue rose mainly because the AstraZeneca milestone payments were recognized over the estimated performance period; reimbursement revenue fell as Ardelyx’s AstraZeneca-related development activity declined.
- R&D expense decreased 8%; G&A expense nearly doubled, primarily due to public-company costs and higher personnel and office expenses. The company reported no product sales and remained loss-making.
- FY 2014 net loss included a $1.6 million non-cash charge from remeasurement of preferred-stock warrant liabilities. Those warrants were exercised and the liability reclassified to equity at the June 2014 IPO.
- At year-end, cash and cash equivalents were $107.3 million, working capital was $89.5 million, and total assets were $113.4 million. The company reported no outstanding debt. Deferred revenue totaled $47.1 million.
- Operating cash flow was positive largely in the context of collaboration receipts and changes in deferred revenue and working capital; it should not be read as evidence of product-level profitability. The IPO generated $61.2 million in net proceeds.
- Management believed existing capital resources would fund its operating plan for at least 12 months from the filing’s perspective, while warning that plans and funding needs could change. No standard product gross margin was reported.
Fourth-quarter detail and material changes
Unaudited Q4 2014 revenue was $6.3 million, operating expenses were $10.3 million, and net loss was $4.0 million. For comparison, Q4 2013 revenue was $8.5 million and net loss was $4.3 million. Quarterly results can fluctuate with collaboration revenue recognition and expenses.
- The June 2014 IPO raised $61.2 million net; preferred stock converted to common stock, materially strengthening reported stockholders’ equity.
- Ardelyx extended its Fremont lease through September 2019 and added office and laboratory space. It reported 34 employees at year-end.
- Management extended the estimated AstraZeneca performance period for tenapanor Phase 2 work from December 2016 to December 2017, affecting the timing of licensing-revenue recognition.
Outlook, risks and contingencies
- Management expected results from the Phase 2a tenapanor trial in patients with stage 3 CKD, type 2 diabetes, albuminuria and elevated blood pressure in Q2 2015. The filing also described AstraZeneca’s discretion to select indications and the possibility of future development milestones, which are not assured.
- At the higher doses in the CKD-5D trial, diarrhea and discontinuations due to diarrhea were higher than expected, particularly in the 30 mg once-daily and twice-daily groups. Diarrhea was also a known tenapanor adverse event in other studies.
- Ardelyx depends substantially on AstraZeneca for tenapanor’s development, manufacture and commercialization. AstraZeneca may discontinue development or terminate the agreement; Sanofi’s NaP2b option and any related future payments are also uncertain.
- Tenapanor had not entered Phase 3 or received regulatory approval as described in this filing. Clinical, regulatory, manufacturing, patent, market-acceptance and reimbursement risks remain material. The filing cites possible future price pressure from the planned inclusion of oral ESRD-related drugs in Medicare’s dialysis bundle beginning in 2024.
- There were no material legal proceedings or off-balance-sheet arrangements reported. Contractual obligations totaled $6.1 million, including $4.2 million in operating lease payments; the filing also lists $0.7 million in purchase commitments and $1.2 million in capital expenditure commitments.
Important facts for investors to verify
- Subsequent trial results, tolerability—especially diarrhea—and the path and timing of any Phase 3 program for tenapanor.
- AstraZeneca’s indication and program decisions, milestone timing and any potential co-funding election; Sanofi’s progress and option decision for NaP2b.
- Cash use and runway relative to the company’s evolving development plan, including any co-funding, pipeline expansion or commercialization costs.
- Revenue-recognition assumptions for deferred AstraZeneca payments and how future collaboration activity may affect reported revenue and operating cash flow.
- Potential reimbursement and pricing effects, competitive developments, and the enforceability and coverage of relevant intellectual property.